Fate Therapeutics Company Profile (NASDAQ:FATE)

About Fate Therapeutics (NASDAQ:FATE)

Fate Therapeutics logoFate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:FATE
  • CUSIP: N/A
  • Web: www.fatetherapeutics.com
Capitalization:
  • Market Cap: $163.18 million
  • Outstanding Shares: 41,415,000
Average Prices:
  • 50 Day Moving Avg: $3.43
  • 200 Day Moving Avg: $3.73
  • 52 Week Range: $1.80 - $5.68
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.48
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $4.11 million
  • Price / Sales: 41.52
  • Book Value: $1.33 per share
  • Price / Book: 3.10
Profitability:
  • EBIDTA: ($34,730,000.00)
  • Net Margins: -887.68%
  • Return on Equity: -67.01%
  • Return on Assets: -48.02%
Debt:
  • Debt-to-Equity Ratio: 0.12%
  • Current Ratio: 8.93%
  • Quick Ratio: 8.93%
Misc:
  • Average Volume: 295,467 shs.
  • Beta: 1.51
  • Short Ratio: 10.43
 

Frequently Asked Questions for Fate Therapeutics (NASDAQ:FATE)

What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) released its earnings results on Monday, August, 14th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.01. The company earned $1.03 million during the quarter, compared to the consensus estimate of $1.02 million. Fate Therapeutics had a negative return on equity of 67.01% and a negative net margin of 887.68%. View Fate Therapeutics' Earnings History.

When will Fate Therapeutics make its next earnings announcement?

Fate Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Fate Therapeutics.

Where is Fate Therapeutics' stock going? Where will Fate Therapeutics' stock price be in 2017?

5 brokerages have issued 1-year price targets for Fate Therapeutics' stock. Their predictions range from $6.00 to $8.00. On average, they anticipate Fate Therapeutics' stock price to reach $7.00 in the next twelve months. View Analyst Ratings for Fate Therapeutics.

What are analysts saying about Fate Therapeutics stock?

Here are some recent quotes from research analysts about Fate Therapeutics stock:

  • 1. According to Zacks Investment Research, "Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. " (9/8/2017)
  • 2. HC Wainwright analysts commented, "With FDA clearing the Investigational New Drug application (IND) for FATE-NK100, we believe Fate made considerable progress to advance its adaptive natural killer (NK) cell program. As the first program of its type, we believe there could have been considerable delays, but we are encouraged by the FDA's decision and would expect similar regulatory approvals in Canada and the UK in the coming quarter. Fate intends to begin its Phase 1 trial in patients with advanced acute myeloid leukemia (AML) with an accelerated doseescalation scheme, agreed to by the FDA, which would employ a single patient at each of four dose levels, provided no dose-limiting toxicities are observed. Once the target therapeutic dose has been safely reached, Fate intends to dose six additional patients. We expect Fate's collaborator at the University of Minnesota (UMN) will be able to enroll this trial briskly and we would expect to see data presented at a medical forum in 2H17. We believe investigators will be looking for a 30% complete response rate, in other words, at least as good as UMN was seeing with its own research. In addition to response rate, Fate will look at disease free survival, minimal residual disease, and persistence. We expect Fate to explore NK100 in solid tumors, submitting a protocol evaluating NK100 in gynecologic malignancies, targeting a mid-2017 start. Separately, we expect NK100 to be evaluated in a combination study with its own IND; we expect a submission in the next couple months. Although we do not include NK100 in our valuation, we believe that positive clinical data could drive significant upside." (3/20/2017)
  • 3. BMO Capital Markets analysts commented, "We are raising our price target to $7 from $4, following 4Q16 earnings that underlined growing interesting in Fate's earlier stage assets, NK100 and iPSC. Our DCF valuation increases as we assign value for these therapies to continue revenue growth beyond ProTmune. We expect ProTmune Phase I interim data in mid-2017 and NK100 to enroll its first AML patient in 2Q17. Fate's hnCD16-iNK could start human trials by early 2018. While we see tremendous potential in the NK100 and iPSC platforms, we wait for clinical validation before including them in our model." (3/17/2017)

Who are some of Fate Therapeutics' key competitors?

Who are Fate Therapeutics' key executives?

Fate Therapeutics' management team includes the folowing people:

  • William H. Rastetter Ph.D., Independent Chairman of the Board
  • J. Scott Wolchko, President, Chief Executive Officer, Principal Executive Officer, Director
  • John D. Mendlein Ph.D., Vice Chairman of the Board
  • Daniel D. Shoemaker Ph.D., Chief Scientific Officer
  • John Ferraro, Vice President - Clinical Operations
  • Wendy Levin, Vice President - Clinical Development
  • Walter Grubb, Vice President - Business Development
  • Cindy Tahl J.D., General Counsel
  • Stewart Abbot Ph.D., Chief Development Officer
  • Chris M. Storgard M.D., Chief Medical Officer

Who owns Fate Therapeutics stock?

Fate Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (14.68%), FMR LLC (10.50%), EcoR1 Capital LLC (6.13%), Redmile Group LLC (3.43%), Vanguard Group Inc. (3.05%) and Kingdon Capital Management L.L.C. (2.78%). Company insiders that own Fate Therapeutics stock include Chris Storgard and William H Rastetter. View Institutional Ownership Trends for Fate Therapeutics.

Who sold Fate Therapeutics stock? Who is selling Fate Therapeutics stock?

Fate Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Kingdon Capital Management L.L.C., FMR LLC, Goldman Sachs Group Inc., Wells Fargo & Company MN and Neuberger Berman Group LLC. View Insider Buying and Selling for Fate Therapeutics.

Who bought Fate Therapeutics stock? Who is buying Fate Therapeutics stock?

Fate Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Northern Trust Corp, TIAA CREF Investment Management LLC, Vanguard Group Inc., Algert Global LLC, Bank of New York Mellon Corp, OxFORD Asset Management LLP and Teachers Advisors LLC. Company insiders that have bought Fate Therapeutics stock in the last two years include Chris Storgard and William H Rastetter. View Insider Buying and Selling for Fate Therapeutics.

How do I buy Fate Therapeutics stock?

Shares of Fate Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Fate Therapeutics' stock price today?

One share of Fate Therapeutics stock can currently be purchased for approximately $4.12.


MarketBeat Community Rating for Fate Therapeutics (NASDAQ FATE)
Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  172 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  235
MarketBeat's community ratings are surveys of what our community members think about Fate Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Fate Therapeutics (NASDAQ:FATE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.00 (69.90% upside)

Analysts' Ratings History for Fate Therapeutics (NASDAQ:FATE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/8/2017Leerink SwannReiterated RatingOutperform -> Outperform$7.00MediumView Rating Details
5/16/2017WedbushReiterated RatingOutperform$7.00HighView Rating Details
3/20/2017HC WainwrightLower Price TargetBuy$8.00 -> $6.00LowView Rating Details
3/18/2017Roth CapitalSet Price TargetBuy$8.00LowView Rating Details
3/17/2017BMO Capital MarketsBoost Price TargetBuy$7.00MediumView Rating Details
5/10/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
11/5/2015Cowen and CompanyReiterated RatingOutperformN/AView Rating Details
10/6/2015Raymond James Financial, Inc.Initiated CoverageOutperform$8.00N/AView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for Fate Therapeutics (NASDAQ:FATE)
Earnings by Quarter for Fate Therapeutics (NASDAQ:FATE)
Earnings History by Quarter for Fate Therapeutics (NASDAQ FATE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.25)N/AView Earnings Details
8/14/2017Q2 2017($0.24)($0.23)$1.02 million$1.03 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.21)($0.24)$1.04 million$1.03 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.28)($0.21)$1.06 million$1.03 millionViewN/AView Earnings Details
11/7/2016Q316($0.29)($0.27)$1.05 million$1.03 millionViewListenView Earnings Details
8/8/2016Q216($0.32)($0.29)$1.02 million$1.03 millionViewN/AView Earnings Details
5/9/2016Q116($0.25)($0.29)$0.84 million$1.32 millionViewN/AView Earnings Details
3/3/2016Q415($0.27)($0.26)$0.58 million$1.08 millionViewN/AView Earnings Details
11/3/2015Q315($0.32)($0.24)$0.46 million$1.03 millionViewN/AView Earnings Details
8/5/2015Q215($0.39)($0.33)$0.31 million$0.33 millionViewN/AView Earnings Details
5/7/2015Q115($0.34)($0.38)ViewListenView Earnings Details
3/12/2015Q414($0.31)($0.30)ViewListenView Earnings Details
11/11/2014Q3 2014($0.29)($0.30)ViewN/AView Earnings Details
8/12/2014Q214($0.36)($0.30)ViewN/AView Earnings Details
5/13/2014Q114($0.32)($0.34)ViewN/AView Earnings Details
3/17/2014Q413($0.27)($0.29)ViewN/AView Earnings Details
11/13/2013Q3($0.32)($4.81)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Fate Therapeutics (NASDAQ:FATE)
2017 EPS Consensus Estimate: ($0.98)
2018 EPS Consensus Estimate: ($1.02)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.24)($0.22)($0.23)
Q2 20172($0.25)($0.24)($0.25)
Q3 20172($0.25)($0.24)($0.25)
Q4 20172($0.26)($0.25)($0.26)
Q1 20181($0.18)($0.18)($0.18)
Q2 20181($0.24)($0.24)($0.24)
Q3 20181($0.28)($0.28)($0.28)
Q4 20181($0.32)($0.32)($0.32)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Fate Therapeutics (NASDAQ:FATE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Fate Therapeutics (NASDAQ:FATE)
Insider Ownership Percentage: 10.88%
Institutional Ownership Percentage: 64.27%
Insider Trades by Quarter for Fate Therapeutics (NASDAQ:FATE)
Institutional Ownership by Quarter for Fate Therapeutics (NASDAQ:FATE)
Insider Trades by Quarter for Fate Therapeutics (NASDAQ:FATE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/23/2016Chris StorgardInsiderBuy37,593$2.66$99,997.38View SEC Filing  
11/23/2016William H RastetterDirectorBuy375,939$2.66$999,997.74View SEC Filing  
6/12/2014Peter D FlynnInsiderSell6,488$7.00$45,416.00View SEC Filing  
6/10/2014Peter D FlynnInsiderSell3,305$7.00$23,135.00View SEC Filing  
5/1/2014Peter D FlynnInsiderSell9,793$7.07$69,236.51View SEC Filing  
4/4/2014Peter D FlynnInsiderSell5,889$8.00$47,112.00View SEC Filing  
4/2/2014Christian WeyerInsiderSell10,000$9.02$90,200.00View SEC Filing  
4/1/2014J Scott WolchkoInsiderSell20,000$9.64$192,800.00View SEC Filing  
3/31/2014Daniel D ShoemakerCTOSell8,653$9.86$85,318.58View SEC Filing  
10/4/2013John MendleinDirectorBuy16,667$6.00$100,002.00View SEC Filing  
10/4/2013Venture Fund Vi Lp ArchMajor ShareholderBuy833,333$6.00$4,999,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Fate Therapeutics (NASDAQ:FATE)
Latest Headlines for Fate Therapeutics (NASDAQ:FATE)
Source:
DateHeadline
americanbankingnews.com logoFate Therapeutics, Inc. (FATE) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - September 22 at 10:10 AM
seekingalpha.com logoWhat 'Fate' Lies Ahead For This ~$4 Biotech Busted IPO? - Seeking Alpha
seekingalpha.com - September 21 at 6:43 PM
americanbankingnews.com logo-$0.25 EPS Expected for Fate Therapeutics, Inc. (FATE) This Quarter
www.americanbankingnews.com - September 21 at 12:24 PM
seekingalpha.com logoFate Therapeutics launches mid-stage study of ProTmune in GvHD; shares ahead 3% - Seeking Alpha
seekingalpha.com - September 19 at 11:38 PM
streetinsider.com logoFate Therapeutics (FATE) Initiates Phase 2 PROTECT Study of ProTmune for Prevention of GvHD
www.streetinsider.com - September 19 at 6:34 PM
reuters.com logoBRIEF-Fate Therapeutics initiates Phase 2 PROTECT study of ProTmune
www.reuters.com - September 19 at 6:34 PM
nasdaq.com logoFate Therapeutics Initiates Phase 2 PROTECT Study of ProTmune™ for Prevention of Acute Graft-versus-Host Disease - Nasdaq
www.nasdaq.com - September 18 at 11:22 PM
finance.yahoo.com logoFate Therapeutics Initiates Phase 2 PROTECT Study of ProTmune™ for Prevention of Acute Graft-versus-Host Disease
finance.yahoo.com - September 18 at 6:22 PM
globenewswire.com logoFate Therapeutics Appoints Jim Beitel as Senior Vice President, Corporate Development - GlobeNewswire (press release)
globenewswire.com - September 14 at 7:15 PM
finance.yahoo.com logoFate Therapeutics Appoints Jim Beitel as Senior Vice President, Corporate Development
finance.yahoo.com - September 14 at 7:15 PM
streetinsider.com logoKeryx Biopharma (KERX) Names Michael Rogers as Chairman Following Resignation of John Butler
www.streetinsider.com - September 13 at 7:54 PM
americanbankingnews.com logoFate Therapeutics, Inc. (FATE) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - September 8 at 11:50 PM
americanbankingnews.com logoFate Therapeutics, Inc. (FATE) Receives Outperform Rating from Leerink Swann
www.americanbankingnews.com - September 8 at 8:42 PM
americanbankingnews.com logoZacks Investment Research Downgrades Fate Therapeutics, Inc. (FATE) to Hold
www.americanbankingnews.com - September 6 at 10:28 PM
americanbankingnews.com logo$1.02 Million in Sales Expected for Fate Therapeutics, Inc. (FATE) This Quarter
www.americanbankingnews.com - September 4 at 1:48 AM
americanbankingnews.com logo-$0.24 Earnings Per Share Expected for Fate Therapeutics, Inc. (FATE) This Quarter
www.americanbankingnews.com - September 2 at 8:26 PM
finance.yahoo.com logoFate Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - September 1 at 6:56 PM
americanbankingnews.com logoFate Therapeutics Inc (FATE) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 1 at 2:44 AM
americanbankingnews.com logoFate Therapeutics, Inc. (FATE) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - August 30 at 12:36 AM
finance.yahoo.com logoMore Immunotherapy Buyouts Likely After Kite Sale
finance.yahoo.com - August 28 at 6:19 PM
nasdaq.com logoFate Therapeutics Announces Issuance of U.S. Patent Covering Use ... - Nasdaq
www.nasdaq.com - August 18 at 12:53 AM
americanbankingnews.com logoFate Therapeutics, Inc. (FATE) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - August 17 at 9:26 PM
reuters.com logoBRIEF-Fate Therapeutics files for mixed shelf of upto $100 mln
www.reuters.com - August 17 at 7:52 PM
americanbankingnews.com logoQ3 2017 EPS Estimates for Fate Therapeutics, Inc. (FATE) Lifted by Wedbush
www.americanbankingnews.com - August 17 at 8:22 AM
americanbankingnews.com logoZacks: Analysts Anticipate Fate Therapeutics, Inc. (FATE) Will Announce Quarterly Sales of $1.02 Million
www.americanbankingnews.com - August 17 at 7:46 AM
streetinsider.com logoFate Therapeutics (FATE) Receives U.S. Patent Covering Use of Viral Transduction Enhancers in Gene Therapy
www.streetinsider.com - August 16 at 11:42 PM
globenewswire.com logoFate Therapeutics Announces Issuance of U.S. Patent Covering Use ... - GlobeNewswire (press release)
globenewswire.com - August 16 at 6:40 PM
finance.yahoo.com logoFate Therapeutics Announces Issuance of U.S. Patent Covering Use of Viral Transduction Enhancers in Gene Therapy
finance.yahoo.com - August 16 at 6:40 PM
seekingalpha.com logoFate Therapeutics' (FATE) CEO Scott Wolchko on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 16 at 5:19 AM
reuters.com logoBRIEF-Fate Therapeutics files for mixed shelf of upto $100 mln
www.reuters.com - August 15 at 7:15 PM
finance.yahoo.com logoBiotech Movers: Fate Shares Spike After Cancer Studies Progress
finance.yahoo.com - August 15 at 7:14 PM
americanbankingnews.com logoFate Therapeutics, Inc. (FATE) Posts Quarterly Earnings Results
www.americanbankingnews.com - August 15 at 1:36 PM
rttnews.com logoFDA Lifts Hold On CVM's Study, FATE On Track, REGN, OPHT, ZYNE All Flunk Trials
www.rttnews.com - August 15 at 5:01 AM
nasdaq.com logoAfter-Hours Earnings Report for August 14, 2017 : SBS, HOLI, EXTR, ATTO, FSM, PLAB, HIL, AST, OCX, FATE, WPRT ... - Nasdaq
www.nasdaq.com - August 14 at 6:56 PM
nasdaq.com logoFate Therapeutics Reports Second Quarter 2017 Financial Results - Nasdaq
www.nasdaq.com - August 14 at 6:56 PM
finance.yahoo.com logoInvestor Network: Fate Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - August 14 at 6:56 PM
finance.yahoo.com logoFate Therapeutics Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 14 at 6:56 PM
finance.yahoo.com logoFate Therapeutics reports 2Q loss
finance.yahoo.com - August 14 at 6:56 PM
finance.yahoo.com logoFate Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 9 at 6:44 PM
streetinsider.com logoFate Therapeutics (FATE) Reports Publication of Preclinical Data in Cancer Research & FDA Clearance of Third IND for FATE-NK100
www.streetinsider.com - August 8 at 11:20 PM
reuters.com logoBRIEF-Fate Therapeutics says FDA cleared third IND application for Fate-NK100
www.reuters.com - August 8 at 11:20 PM
nasdaq.com logoHealth Care Sector Update for 08/08/2017: FATE,FGEN,BIOA - Nasdaq
www.nasdaq.com - August 8 at 6:19 PM
reuters.com logoBRIEF-Fate Therapeutics says FDA cleared third IND application for Fate-NK100​ - Reuters
www.reuters.com - August 8 at 6:19 PM
nasdaq.com logoFate Therapeutics Announces Publication of Preclinical Data in Cancer Research and FDA Clearance of Third IND for ... - Nasdaq
www.nasdaq.com - August 8 at 6:19 PM
americanbankingnews.com logoFate Therapeutics, Inc. (NASDAQ:FATE) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - August 7 at 11:50 PM
americanbankingnews.com logoFate Therapeutics, Inc. (FATE) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - August 7 at 10:34 PM
finance.yahoo.com logoFate Therapeutics to Webcast Conference Call Reporting Second Quarter 2017 Financial Results
finance.yahoo.com - August 7 at 6:46 PM
americanbankingnews.com logoFate Therapeutics, Inc. (FATE) Sees Significant Growth in Short Interest
www.americanbankingnews.com - July 16 at 7:06 AM
reuters.com logoBRIEF-Fate Therapeutics to amend and restate loan and security agreement
www.reuters.com - July 14 at 5:15 PM
finance.yahoo.com logoETFs with exposure to Fate Therapeutics, Inc. : July 13, 2017
finance.yahoo.com - July 13 at 7:55 PM

Social

Chart

Fate Therapeutics (FATE) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff